Report ID: 10070522 |
Published Date: 21 Mar 2025 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
Global Erectile Dysfunction Drugs Market Highlights Over 2022 - 2031
The global erectile dysfunction drugs market is estimated to garner around USD 2.5 billion in revenue by 2031 by growing at a CAGR of nearly 3% over the forecast period, i.e., 2022 – 2031. The growth of the market can be attributed to the high prevalence of erectile dysfunction on the back of incidences of chronic diseases, including neurogenic disorders, hypertension, diabetes, and psychological disorders. For instance, according to the World Health Organization, as of 2021, the prevalence of hypertension has increased to an estimated number of 1.28 billion adults aged 30 to 79 years globally, with the majority (two-thirds) living in low and middle-income countries. Additionally, the rising adoption of sedentary lifestyle, alcoholism, and smoking are significantly increasing the risk of erectile dysfunction diseases, which is expected to boost the demand for erectile dysfunction drugs in the upcoming years.
CLICK TO DOWNLOAD A SAMPLE REPORT
The COVID-19 pandemic led to increasing inactive lifestyle and associated stress, coupled with increasing alcoholism and smoking, causing erectile dysfunction disorders and other hormonal diseases. This is expected to boost the growth of the erectile dysfunction drugs market globally.
However, the high cost of the drugs and associated side effects, coupled with stringent government regulations, and increasing availability of cheap and fake erectile dysfunction drugs in the market are the key factors restraining the growth of the market.
The market is segmented by products into Viagra (Sildenafil Citrate), Cialis (Tadalafil), Vardenafil, Levitra/Staxyn, Stendra/Spedra (Avanafil), Zydena (Udenafil), Vitaros (Alprostadil Cream), and others. Among these segments, the Viagra (Sildenafil Citrate) segment is anticipated to hold the major share over the forecast period. The growth can be attributed to brand loyalty and advantages associated with the drug, such as high efficacy. It also helps men to get an erection by increasing blood flow to the penis.
Global Erectile Dysfunction Drugs Market Regional Synopsis
Regionally, the global erectile dysfunction drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The market in North America region is estimated to witness significant growth over the forecast period on the back of the high demand for erectile dysfunction drugs. For instance, in 2019, Viagra generated over USD 400 million in the United States. Additionally, the presence of established healthcare infrastructure and growing R&D initiatives for the advancement of drugs are also expected to boost the market growth of the region.
Asia Pacific region is estimated to witness the fastest growth over the forecast period owing to the rising prevalence of infections causing erectile dysfunction, the growing base geriatric population, and the increasing number of generic drug industries. Moreover, untapped opportunities and increasing awareness related to erectile dysfunction are predicted to boost the market growth of the region.
Market Segmentation
Our in-depth analysis of the global erectile dysfunction drugs market includes the following segments:
By Products
-
Viagra (Sildenafil Citrate)
-
Cialis (Tadalafil)
-
Vardenafil
-
Levitra/Staxyn
-
Stendra/Spedra (Avanafil)
-
Zydena (Udenafil)
-
Vitaros (Alprostadil Cream)
-
Others
By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
Growth Drivers and Challenges Impacting the Growth of the Global Erectile Dysfunction Drugs Market
Growth Drivers
-
High prevalence of erectile dysfunction on the back of incidences of chronic diseases
-
Rising adoption of sedentary lifestyle, alcoholism, and smoking causing erectile dysfunction diseases
Challenges
-
High cost of the drugs and associated side effects, coupled with stringent government regulations
-
Increasing availability of cheap and fake erectile dysfunction drugs in the market
Key Companies Dominating the Global Erectile Dysfunction Drugs Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global erectile dysfunction drugs market that are included in our report are Glenmark Pharmaceuticals Limited, Pfizer Inc., Bayer AG, Eli Lilly and Company, Ferring B.V., BioSpace, Vivus LLC, SK chemicals, Questex, Lupin, and others.
Latest Developments in the Global Erectile Dysfunction Drugs Market:
-
December 2020: Glenmark Pharmaceuticals Ltd. received final approval from the United States Food and Drug Administration (FDA) for Tadalafil tablets which are used to treat erectile dysfunction and enlarged prostate.
-
March 2019: Lupin received approval for its Sildenafil Tablets USP, 25 mg, 50 mg, and 100 mg from the United States Food and Drug Administration (FDA) to market a generic version of Pfizer Inc’s Viagra Tablets, 25 mg, 50 mg, and 100 mg.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
Frequently Asked Question
The market is segmented by products, distribution channel, and by region.
The Viagra (Sildenafil Citrate) segment is anticipated to hold largest market size in value and display significant growth opportunities.
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
Report ID: 10070522 |
Published Date: 21 Mar 2025 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
